Developmental dysplasia of the hip 3

Summary

Developmental dysplasia of the hip 3 (MONDO:0958037) is a disease with 1 cohort gene.

At a glance

• Cohort genes: 1
• ClinVar variants: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	developmental dysplasia of the hip 3
Mondo ID	MONDO:0958037
OMIM	620690
UMLS	C5882750
MedGen	1850976
Is cancer (heuristic)	no

Data availability: 8 ClinVar variants · 2 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › developmental dysplasia of the hip › developmental dysplasia of the hip 3

Related subtypes (3): developmental dysplasia of the hip 1, developmental dysplasia of the hip 2, developmental dysplasia of the hip 4

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

8 retrieved; paginated sample, class counts are floors:

4 pathogenic, 3 uncertain significance, 1 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
2691743	NM_002332.3(LRP1):c.5347C>T (p.Arg1783Trp)	LRP1	Pathogenic	no assertion criteria provided
2691744	NM_002332.3(LRP1):c.6386C>A (p.Thr2129Lys)	LRP1	Pathogenic	no assertion criteria provided
2691745	NM_002332.3(LRP1):c.670C>G (p.Pro224Ala)	LRP1	Pathogenic	no assertion criteria provided
2691746	NM_002332.3(LRP1):c.2798-4C>A	LRP1	Pathogenic	no assertion criteria provided
930178	NM_002332.3(LRP1):c.300C>T (p.Asp100=)	LRP1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
3575004	NM_002332.3(LRP1):c.1284G>A (p.Ser428=)	LRP1	Uncertain significance	criteria provided, single submitter
3891589	NM_002332.3(LRP1):c.1214T>C (p.Ile405Thr)	LRP1	Uncertain significance	criteria provided, single submitter
3891590	NM_002332.3(LRP1):c.506G>A (p.Gly169Asp)	LRP1	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 7 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
LRP1	Moderate	Autosomal dominant	developmental dysplasia of the hip 3	7

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
LRP1	Orphanet:2340	Keratosis follicularis spinulosa decalvans
LRP1	Orphanet:79100	Atrophoderma vermiculata

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
LRP1	HGNC:6692	ENSG00000123384	Q07954	Prolow-density lipoprotein receptor-related protein 1	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
LRP1	Prolow-density lipoprotein receptor-related protein 1	Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
LRP1	Other/Unknown	no		LDLR_classB_rpt, EGF-type_Asp/Asn_hydroxyl_site, EGF

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ascending aorta	1
descending thoracic aorta	1
stromal cell of endometrium	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
LRP1	293	ubiquitous	marker	stromal cell of endometrium, descending thoracic aorta, ascending aorta

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
LRP1	2,662

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
LRP1	Q07954	7

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 9. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Scavenging of heme from plasma	1	878.5×	0.007	LRP1
Binding and Uptake of Ligands by Scavenger Receptors	1	543.8×	0.007	LRP1
Metabolism of fat-soluble vitamins	1	380.7×	0.007	LRP1
Visual phototransduction	1	259.6×	0.007	LRP1
Retinoid metabolism and transport	1	248.3×	0.007	LRP1
Metabolism of vitamins and cofactors	1	116.5×	0.013	LRP1
Sensory Perception	1	95.2×	0.014	LRP1
Vesicle-mediated transport	1	34.8×	0.032	LRP1
Metabolism	1	11.6×	0.086	LRP1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of transcytosis	1	16852.0×	0.001	LRP1
positive regulation of lipid transport	1	8426.0×	0.001	LRP1
positive regulation of reverse cholesterol transport	1	8426.0×	0.001	LRP1
astrocyte activation involved in immune response	1	4213.0×	0.001	LRP1
negative regulation of platelet-derived growth factor receptor-beta signaling pathway	1	4213.0×	0.001	LRP1
regulation of extracellular matrix disassembly	1	3370.4×	0.001	LRP1
positive regulation of lysosomal protein catabolic process	1	3370.4×	0.001	LRP1
amyloid-beta clearance by transcytosis	1	2407.4×	0.002	LRP1
amyloid-beta clearance by cellular catabolic process	1	2106.5×	0.002	LRP1
positive regulation of amyloid-beta clearance	1	2106.5×	0.002	LRP1
regulation of extracellular matrix organization	1	1872.4×	0.002	LRP1
transcytosis	1	1685.2×	0.002	LRP1
negative regulation of smooth muscle cell migration	1	1532.0×	0.002	LRP1
enzyme-linked receptor protein signaling pathway	1	1296.3×	0.002	LRP1
lipoprotein transport	1	991.3×	0.002	LRP1
amyloid-beta clearance	1	936.2×	0.002	LRP1
aorta morphogenesis	1	887.0×	0.002	LRP1
apoptotic cell clearance	1	887.0×	0.002	LRP1
positive regulation of endocytosis	1	802.5×	0.002	LRP1
lysosomal transport	1	702.2×	0.002	LRP1
positive regulation of cholesterol efflux	1	624.1×	0.002	LRP1
negative regulation of SMAD protein signal transduction	1	601.9×	0.002	LRP1
retinoid metabolic process	1	495.6×	0.003	LRP1
cellular response to amyloid-beta	1	391.9×	0.004	LRP1
negative regulation of Wnt signaling pathway	1	343.9×	0.004	LRP1
receptor internalization	1	324.1×	0.004	LRP1
positive regulation of protein localization to plasma membrane	1	271.8×	0.004	LRP1
phagocytosis	1	240.7×	0.005	LRP1
receptor-mediated endocytosis	1	221.7×	0.005	LRP1
transport across blood-brain barrier	1	179.3×	0.006	LRP1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
LRP1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	LRP1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
LRP1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.